3.8 Article

News and Views Stimulating Research and Development of Pharmaceutical Products for Neglected Diseases

Journal

EUROPEAN JOURNAL OF HEALTH LAW
Volume 15, Issue 4, Pages 391-409

Publisher

BRILL ACADEMIC PUBLISHERS
DOI: 10.1163/157180908X338278

Keywords

neglected diseases; human rights; pharmaceutical research and development; patents; Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS); incentive mechanisms for the stimulation of research and development of medicinal products

Categories

Ask authors/readers for more resources

This article provides an introduction to the problem of pharmaceutical research and development of medicinal products for neglected diseases in developing countries. The prevailing market-based intellectual property incentive model of global pharmaceutical innovation has focussedhealthresearch priorities mainly on needs of industrialized countries. Increased international attention to the lack of health tools to prevent or treat diseases affecting impoverished regions has raised the discussion on how to encourage sustainable innovation in this area with little or no market. Proposals include models such as for example prize funds, advanced purchase commitments patent pools or creative licensing strategies and seek to complement the current intellectual property based incentive mechanism and government's innovation policy instruments such as tax credits or public research funds. Indispensable requirement to tackle the issue of neglected diseases, however, is a concerted commitment of all stakeholders on national and international levels.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available